Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, and Alvin J. Siteman Cancer Center, St. Louis, MO, United States of America.
Division of Oncology, Department of Medical Oncology, Washington University School of Medicine, and Alvin J. Siteman Cancer Center, St. Louis, MO, United States of America; School of Social Work, College for Public Health and Social Justice, Saint Louis University, St. Louis, MO, United States of America.
Gynecol Oncol. 2021 Jun;161(3):700-704. doi: 10.1016/j.ygyno.2021.02.027. Epub 2021 Feb 26.
To determine the association between scores from a 25-item patient-reported Rockwood Accumulation of Deficits Frailty Index (DAFI) and survival outcomes in gynecologic cancer patients.
A frailty index was constructed from the SEER-MHOS database. The DAFI was applied to women age ≥ 65 diagnosed with all types of gynecologic cancers between 1998 and 2015. The impact of frailty status at cancer diagnosis on overall survival (OS) was analyzed using Kaplan-Meier curves and Cox proportional hazards regression.
In this cohort (n = 1336) the median age at diagnosis was 74 (range 65-97). Nine hundred sixty-two (72%) women were Caucasian and 132 (10%) were African-American. Overall, 651(49%) of patients were considered frail. On multivariate analysis, frail patients had a 48% increased risk for death (aHR 1.48; 95% CI 1.29-1.69; P < 0.0001). Each 10% increase in frailty index was associated with a 16% increased risk of death (aHR, 1.16; 95% CI, 1.11 to 1.21; P < 0.0001). In subgroup analyses of the varying cancer types, the association of frailty status with prognosis was fairly consistent (aHR 1.15-2.24). The DAFI was more prognostic in endometrial (aHR 1.76; 95% CI 1.41-2.18, P < 0.0001) and vaginal/vulvar (aHR 1.94; 95% CI 1.34-2.81, P = 0.0005) cancers as well as patients with loco-regional disease (aHR 1.94; 95% CI 1.62-2.33, P < 0.0001).
Frailty appears to be a significant predictor of mortality in gynecologic cancer patients regardless of chronological age. This measure of functional age may be of particular utility in women with loco-regional disease only who otherwise would have a favorable prognosis.
确定 25 项患者报告的 Rockwood 累积缺陷衰弱指数(DAFI)评分与妇科癌症患者生存结局之间的关联。
从 SEER-MHOS 数据库构建衰弱指数。将 DAFI 应用于 1998 年至 2015 年间诊断为所有类型妇科癌症且年龄≥65 岁的女性。使用 Kaplan-Meier 曲线和 Cox 比例风险回归分析癌症诊断时的虚弱状态对总生存(OS)的影响。
在该队列(n=1336)中,中位诊断年龄为 74 岁(范围 65-97 岁)。962(72%)名女性为白种人,132(10%)名女性为非裔美国人。总体而言,651(49%)名患者被认为虚弱。多变量分析显示,虚弱患者死亡风险增加 48%(aHR 1.48;95%CI 1.29-1.69;P<0.0001)。衰弱指数每增加 10%,死亡风险增加 16%(aHR,1.16;95%CI,1.11 至 1.21;P<0.0001)。在不同癌症类型的亚组分析中,虚弱状态与预后的关联相当一致(aHR 1.15-2.24)。DAFI 在子宫内膜(aHR 1.76;95%CI 1.41-2.18,P<0.0001)和阴道/外阴(aHR 1.94;95%CI 1.34-2.81,P=0.0005)癌症以及局部区域疾病患者中更具预后意义(aHR 1.94;95%CI 1.62-2.33,P<0.0001)。
虚弱似乎是妇科癌症患者死亡的一个重要预测因素,与实际年龄无关。这种功能年龄的衡量标准在仅具有局部区域疾病且预后良好的女性中可能特别有用。